Solid dispersion comprising poorly soluble donepezil salt and method for preparing same

A solid dispersion of donepezil pamoate with a biodegradable polymer in a biodegradable release system addresses the challenges of drug release and safety in existing formulations, achieving sustained drug delivery and improved compliance for Alzheimer's treatment.

WO2024248363A1PCT designated stage expired Publication Date: 2024-12-05DAEWOONG PHARM CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006517
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-14
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods for producing long-acting injectable donepezil formulations using biodegradable release-controlling polymers face challenges such as difficulty in controlling drug release, low drug loading, and the use of organic solvents, which affect safety and compliance in patients with advanced Alzheimer's disease.

Method used

A solid dispersion containing a poorly soluble salt of donepezil, such as donepezil pamoate, combined with a biodegradable release-controlling polymer, is developed to achieve a high drug content and sustained release profile without the use of organic solvents, using hot melt extrusion and micronization processes to enhance bioavailability and stability.

Benefits of technology

The solid dispersion formulation provides a long-lasting drug release profile for over four weeks, improving medication compliance and safety by maintaining consistent blood concentrations and avoiding initial burst release, while simplifying the manufacturing process and eliminating organic solvent risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006517_05122024_PF_FP_ABST
    Figure KR2024006517_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: a solid dispersion comprising a poorly soluble donepezil salt or hydrate or solvate thereof that has an acetylcholine esterase inhibitory effect; a method for preparing same; and a pharmaceutical composition for parenteral administration, comprising the solid dispersion and having an improved drug content of donepezil. The solid dispersion comprising a poorly soluble donepezil salt and a biodegradable release-controlling polymer, according to the present invention, is suitable for preparing a long-acting parenteral pharmaceutical composition having an improved drug content of donepezil. The parenteral pharmaceutical composition according to the present invention can reduce a dose as the drug content of donepezil increases, and can significantly increase the therapeutic effect and medication compliance by maintaining the blood concentration of the drug for a long period of time. The solid dispersion comprising a poorly soluble donepezil salt and a biodegradable release-controlling polymer, according to the present invention, has a relatively simple preparation process, does not cause initial burst problems, and does not use an organic solvent, thus significantly increasing in vivo safety.
Need to check novelty before this filing date? Find Prior Art

Description

Solid dispersion containing a poorly soluble salt of donepezil and a method for producing the same

[0001] The present invention relates to a solid dispersion comprising a poorly soluble salt of donepezil, a hydrate thereof, or a solvate thereof having an acetylcholine esterase inhibitory effect, and a method for producing the same.

[0002] The present invention also relates to a pharmaceutical composition for parenteral administration having improved drug content of donepezil including the above solid dispersion.

[0003] Alzheimer's disease is the leading cause of dementia in the elderly. Donepezil, an acetylcholinesterase inhibitor, is widely used as a drug treatment for Alzheimer's disease, and is mostly administered orally in tablet form. However, in patients with advanced Alzheimer's disease, daily oral medication is limited due to cognitive impairments such as memory, language, and learning decline, as well as mental disorders such as depression, psychosis, and delusions. Therefore, there is a need for improved dosage forms that improve medication adherence.

[0004] Meanwhile, the manufacture of microspheres using a biodegradable release-controlled polymer was attempted as a method for manufacturing a pharmaceutical composition suitable for long-acting injections that can maintain drug concentrations for a long period of time while improving patient convenience and compliance by reducing the frequency of drug administration.

[0005] Microspheres using biodegradable controlled-release polymers can be manufactured using various methods, including emulsion-solvent evaporation, spray drying, and coacervation. Among these, emulsion-solvent evaporation is the most commonly used. Methods for manufacturing microspheres using emulsion-solvent evaporation are described in U.S. Patent Publication No. 2011 / 0218216, and Korean Patent Nos. 10-2237737, 10-2047982, and 10-2091114. However, this manufacturing method using the emulsion-solvent evaporation method has several problems, such as the difficulty in controlling the pores on the surface of the microparticles that are created during the organic solvent removal process, the difficulty in mass production, the low drug content within the microparticles of less than 20%, requiring a very large dosage for actual patient application, and the fact that the residual organic solvent affects the safety of the drug.

[0006] Meanwhile, there have been attempts to develop a poorly soluble salt of donepezil as another method for manufacturing a long-acting injectable drug without using microspheres.

[0007] U.S. Patent Nos. 11,014,885, 11,197,850, 10,952,958, and International Publication No. 2013005094 describe methods for preparing donepezil pamoate or donepezil hemipamoate salts by reacting donepezil with pamoic acid. From a chemical structural perspective, these donepezil pamoate salts can form poorly soluble salts through strong ionic bonds between the cationic tertiary amine of donepezil and the anionic carboxylic acid of pamoic acid, resulting in low solubility under physiological conditions. Due to this low solubility, donepezil pamoate salts offer new opportunities for designing improved drug delivery systems. However, the above prior art presents a technique for preparing an aqueous microcrystal suspension by mixing donepezil pamoate salt microcrystals with a diluent including carboxymethyl cellulose sodium, poloxamer 188 or Tween 80, and injecting the same intramuscularly. However, in reality, such a preparation has a limitation in that it is difficult to maintain long-term efficacy for more than two weeks.

[0008] Meanwhile, Korean Patent No. 10-1811797 describes a method for manufacturing PLGA microspheres containing a sparingly soluble salt of donepezil, including donepezil pamoate salt. However, the method for manufacturing PLGA microspheres using the oil-in-water (O / W) solvent evaporation method causes pores and cracks within the microspheres during the solvent removal process, which makes it difficult to control drug release, such as initial burst, and limits the drug loading amount to a low level of 20%. Furthermore, the presence of organic solvents remaining within the microspheres can act as a major hurdle in product development.

[0009] Accordingly, the inventors of the present invention have developed a pharmaceutical composition suitable for long-acting injection with a high drug content of donepezil without using an organic solvent through research into the development of a new solid dispersion suspension comprising a poorly soluble salt of donepezil and a biodegradable release-controlled polymer, and have completed the present invention.

[0010] The purpose of the present invention is to provide a pharmaceutical composition for parenteral administration that has a high drug content of donepezil and can maintain a drug concentration in the blood for a long period of time without the problem of initial rapid drug release.

[0011] To achieve the above purpose, the present invention provides a solid dispersion comprising a pharmaceutically acceptable sparingly soluble salt of donepezil, a hydrate thereof, or a solvate thereof as an active ingredient; and a biodegradable release-controlling polymer, and having a drug content of 20 to 50 wt%.

[0012] A solid dispersion is a system in which a drug is homogeneously dispersed throughout a solid matrix. During the manufacturing process of a solid dispersion, the drug particle size is reduced, the surface area of ​​the drug particles is increased, and the drug is partially or completely converted to an amorphous state. Therefore, solid dispersions are generally used as a technique to improve the solubility of drugs. In particular, poorly soluble drugs usually have low solubility due to high crystallinity. When poorly soluble drugs are manufactured into a solid dispersion, the solubility is improved by reducing the crystallinity of the drug, and thus the bioavailability of the drug is improved. Therefore, solid dispersions are often used to improve the solubility of poorly soluble drugs.

[0013] However, the present inventors have devised a technique for forming a solid dispersion using a pharmaceutically acceptable, sparingly soluble salt of donepezil, a hydrate thereof, or a solvate thereof, and a biodegradable release-controlled polymer, in order to manufacture a pharmaceutical composition for parenteral administration that has a high drug content of donepezil and can maintain a drug concentration in the blood for a long period of time without the problem of initial rapid drug release.

[0014] Unlike the general purpose of manufacturing a solid dispersion to improve the solubility of a poorly soluble drug, the present invention is completely different from the conventional purpose of selecting a conventional solid dispersion as a drug release system in that it uses a pharmaceutically acceptable poorly soluble salt of donepezil, a hydrate thereof, or a solvate thereof to lower the solubility and dissolution rate of donepezil and thereby implement a long-term drug release profile.

[0015] This novel idea of ​​manufacturing donepezil as a solid dispersion using a biodegradable controlled-release polymer was initiated as an attempt to solve the problem of the prior art of forming microspheres using a biodegradable controlled-release polymer for sustained release of donepezil.

[0016] Manufacturing donepezil's poorly soluble salt into microspheres via emulsion-solvent evaporation not only complicates the manufacturing process and inevitably requires the use of organic solvents, but also presents challenges in controlling drug release, such as the initial burst, and limits the drug loading capacity. However, formulating donepezil's poorly soluble salt into a general suspension can increase the drug content within the formulation, but the long-term sustained release of the drug is poor, making development into a long-acting injection impossible.

[0017] However, as described in the present invention, when donepezil is manufactured as a solid dispersion using a biodegradable release-controlled polymer, not only can the drug release duration be improved compared to formulating a poorly soluble salt of donepezil in a powder state, but also, compared to microspheres manufactured using an emulsion-solvent evaporation method, problems such as the complexity of the manufacturing process, the use of organic solvents, the difficulty of controlling drug release such as initial burst, and the limitation of drug loading amount can be easily solved.

[0018] The solid dispersion according to the present invention comprises a pharmaceutically acceptable sparingly soluble salt of donepezil, a hydrate thereof, or a solvate thereof; and a biodegradable release-controlling polymer.

[0019] In this specification, a pharmaceutically acceptable sparingly soluble salt of donepezil is also referred to as a sparingly soluble salt of donepezil. A sparingly soluble salt of donepezil refers to a salt of donepezil in which the free base of donepezil forms a stable salt through ionic bonding with an inorganic or organic acid, and dissociation or hydration is reduced in an aqueous solution, so that the solubility thereof does not substantially increase or rather decreases compared to the free base of donepezil.

[0020] Although not limited thereto, the pharmaceutically acceptable sparingly soluble salt of donepezil may be a pamoate, xinafoate or napadicylate salt. Donepezil pamoate is meant to include both donepezil monopamoate and donepezil hemipamoate. However, donepezil monopamoate is in a metastable state, and is difficult to exist as donepezil monopamoate in an aqueous solution, and even when donepezil monopamoate is formed, it is converted to donepezil hemipamoate, which is in a more stable state. Therefore, preferably, the donepezil pamoate salt in the present invention may be donepezil hemipamoate.

[0021] Although it may be desirable to increase the solubility of donepezil in oral pharmaceutical compositions, it is not desirable to use a salt of donepezil with high solubility in the preparation of long-acting parenteral pharmaceutical compositions.

[0022] According to the results of a solubility test in a PBS solution at pH 7.4 (extracellular fluid-like conditions) performed by the present researchers, the solubility of the free base of donepezil was approximately 296.2 ug / mL, whereas the solubility of donepezil pamoate, one of the less soluble salts of donepezil, was approximately 5.8 ug / mL. The less soluble salts of donepezil may slow down the drug release rate when administered into the body due to their low solubility.

[0023] The drug content contained in the solid dispersion according to the present invention may be 20 to 50 wt%. While there is no specific limitation on the lower limit of the drug content, a content of 20 wt% or more is advantageous for providing a long-acting parenteral pharmaceutical composition. While a drug content exceeding 50 wt% is permissible, a content of 50% or less is preferred for convenience in the manufacturing process of the solid dispersion.

[0024] Although not limited thereto, the drug content included in the solid dispersion according to the present invention may include all lower numerical ranges within the above range, such as, for example, 20 to 40 wt% (e.g., 20 to 30 wt%, 20 to 35 wt%, 25 to 35 wt%, 25 to 40 wt%, 30 to 40 wt%, 35 to 40 wt%), 30 to 50 wt% (e.g., 35 to 45 wt%, 35 to 50 wt%, 40 to 50 wt%, 45 to 50 wt%).

[0025] In the present invention, a biodegradable release-controlled polymer is used together with a poorly soluble salt of donepezil to ensure sustained drug release.

[0026] A biodegradable controlled-release polymer refers to a polymer that, when administered into the body, biodegrades over time, allowing a drug mixed with the polymer to be slowly released. The biodegradable controlled-release polymer used in the solid dispersion according to the present invention is selected from additives that can be administered parenterally, and may be selected from the group consisting of, but not limited to, polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), and mixtures thereof.

[0027] Although not limited thereto, the ratio of polylactide to polyglycolide in the poly(lactide-co-glycolide), i.e., PLGA copolymer, may be from 50:50 to 95:5, for example, 50:50, 65:35, 75:25, or 85:15.

[0028] Although not limited thereto, the biodegradable controlled-release polymer may have a weight average molecular weight of 4,000 to 50,000. For example, the weight average molecular weight of the biodegradable polymer includes all lower numerical ranges within the above range, such as a weight average molecular weight of 4,000 to 15,000, a weight average molecular weight of 7,000 to 17,000, a weight average molecular weight of 5,000 to 20,000, a weight average molecular weight of 10,000 to 18,000, and a weight average molecular weight of 18,000 to 28,000.

[0029] For example, RESOMER from Evonik Rohm GmbH is a biodegradable release-controlled polymer used in the present invention. ® Polylactide, polyglycolide, poly(lactide-co-glycolide) under the trade name can be used alone or in blends. For example, R202H, R202S, R203H, R203S, RG502H, RG503H, RG653H, RG752H, RG752S, RG753H, RG753S can be used alone or in blends.

[0030] On the other hand, the biodegradable controlled-release polymer may have an intrinsic viscosity of, but is not limited to, 0.1 to 1 dl / g, for example, 0.1 to 0.8 dl / g, 0.1 to 0.6 dl / g, 0.1 to 0.5 dl / g, 0.1 to 0.4 dl / g, 0.1 to 0. 3 dl / g. The type of the biodegradable controlled-release polymer, a suitable molecular weight or blending ratio, an intrinsic viscosity, and the like can be appropriately selected by those skilled in the art in consideration of the decomposition rate of the biodegradable polymer and the resulting drug release rate.

[0031] Methods for producing solid dispersions are well known in the art, and for example, solid dispersions can be produced using an emulsion method, a spray drying method, or a hot melt extrusion method.

[0032] The solid dispersion according to the present invention may be manufactured by, but is not limited to, hot melt extrusion. Hot melt extrusion is a method of encapsulating a drug without using an organic solvent by applying heat higher than the melting point or glass transition temperature (in the case of polymers) of the carrier. When hot melt extrusion is used, for example, the solid dispersion filament may be formed through a conventional hot melt extruder and then milled to obtain micronization.

[0033] The above-mentioned micronization can be performed through general dry milling and / or wet milling using a conventional mill capable of micronizing particles, such as a Z-mill, a hammer mill, a ball mill, or a fluid energy mill. In addition, a size classification method, such as a sieving method using a sieve or air current classification, can be used to refine the particle size.

[0034] The solid dispersion according to the present invention may have an average particle size of 200 um or less, 1 to 200 um, for example, 1 to 150 um, 1 to 100 um, 2 to 140 um, 5 to 120 um, 10 to 100 um, or 20 to 80 um.

[0035] Additionally, but not limited thereto, the solid dispersion according to the present invention may have d(50) of 5 to 100 um, for example, 5 to 60 um, 10 to 50 um.

[0036] In this specification, the average particle size means the Volume weighted Mean D[4,3] value as the center of gravity of the distribution, respectively, as the average of the volume or mass. In this specification, the particle size of the drug is also expressed based on the particle size distribution such as D(X) = Y (where X and Y are positive numbers). D(X) = Y means that when the particle size distribution of the drug obtained by measuring the particle diameter of a certain drug in a formulation is expressed by a cumulative curve, the particle diameter at the point where the particle size is X% (% is calculated based on the number, volume, or weight) when the particle size is accumulated in order of smallness is Y. For example, D(10) represents the particle diameter at the point where the particle size of the drug is accumulated in order of smallness is 10%, D(50) represents the particle diameter at the point where the particle size of the drug is accumulated in order of smallness is 50%, and D(90) represents the particle diameter at the point where the particle size of the drug is accumulated in order of smallness is 90%.

[0037] Whether the particle size distribution D(X) represents a percentage of the total cumulative particles by number, volume, or weight depends on the method used to measure the particle size distribution. Methods for measuring particle size distributions and the type of percentages associated with them are well known in the art. For example, when measuring particle size distributions by the well-known laser diffraction method, the X value in D(X) represents the percentage calculated by volume average. It is well known to those skilled in the art that particle size distribution measurement results obtained by a particular method can be correlated with those obtained by other techniques based on experience through routine experiments. For example, laser diffraction is sensitive to particle volume and provides a volume average particle size, which corresponds to a weight average particle size at constant density.

[0038] In the present invention, the average particle size and particle size distribution of the solid dispersion can be measured using a commercially available device based on the laser diffraction / scattering method based on Mie theory. For example, measurement is performed using a commercially available device such as the Mastersizer laser diffraction device from Malvern Instruments. This device irradiates particles with a helium-neon laser beam and a blue light-emitting diode, causing scattering to occur, and a light scattering pattern appears on the detector. By interpreting this light scattering pattern according to Mie theory, the particle diameter distribution is obtained.

[0039] In the present invention, it may be desirable for the solid dispersion to have a uniform particle size distribution. Although not limited thereto, the uniform particle size distribution of the particles can be confirmed using the span value. Span value = (D(90)-D(10)) / D(50). The smaller the span value (the higher the uniformity), the higher the injectability, and thus, the deviation in the dosage can be reduced when administering a suspension formulation. Although not limited thereto, the span value of the solid dispersion according to the present invention may be 10 or less, for example, 1 to 7, preferably 1 to 4.

[0040] The present invention also provides a method for producing the solid dispersion.

[0041] The method for producing a solid dispersion according to the present invention comprises the steps of forming a solid dispersion filament by high-temperature melt extrusion of a mixture of donepezil or a pharmaceutically acceptable sparingly soluble salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient; and a biodegradable release-controlling polymer; and

[0042] It may include a step of crushing and finely dividing the above solid dispersion filaments.

[0043] More specifically, in step 1 of the above manufacturing method, the solid dispersion filament can be formed through a hot-melt extruder, and various shapes of the solid dispersion filament can be formed depending on the temperature, extrusion RPM, and nozzle type.

[0044] In the second step of the above manufacturing method, the solid dispersion filaments can be ground using a conventional mill. Grinding can be performed by dry grinding and / or wet grinding. Since wet grinding is advantageous in grinding into a smaller particle size than dry grinding, it may be preferable to sequentially perform wet grinding after dry grinding. For example, in the case of dry grinding, sizing and micronization can be performed using a conical mill, and various sizes of fine particles can be formed depending on the RPM and sieve size. In the case of wet grinding, micronization can be performed using a bead mill, and various sizes of fine particles can be formed depending on the RPM and sieve size.

[0045] Additionally, the manufacturing method may further include a step of lyophilizing the undifferentiated solid dispersion. A lyophilized solid dispersion may be preferred to ensure product stability.

[0046] The solid dispersion according to the present invention has improved long-term drug release compared to the case where the poorly soluble salt of donepezil itself is used, can solve the problem of initial burst drug release compared to microspheres containing the poorly soluble salt of donepezil, can overcome the limitation of drug loading amount, has a relatively simple manufacturing process, and does not use an organic solvent, so it does not affect human safety.

[0047] The present invention provides a pharmaceutical composition for parenteral administration comprising the above solid dispersion.

[0048] Although not limited thereto, the pharmaceutical composition for parenteral administration according to the present invention may be a suspension.

[0049] When the pharmaceutical composition for parenteral administration according to the present invention is a suspension, the pharmaceutical composition of the present invention can be formulated by selecting a dispersion medium exhibiting excellent dispersibility, and can also include pharmaceutically acceptable additives such as thickeners, surfactants, isotonic agents, buffers, and pH regulators within a range that does not impair the effects of the present invention.

[0050] The pharmaceutical composition for parenteral administration according to the present invention may be an injection. The injection may be suitable for subcutaneous or intramuscular administration.

[0051] In one specific example, when the pharmaceutical composition for parenteral administration is an injection, the solid dispersion may be present in a separate vial from the dispersion medium and may be prepared as a suspension immediately prior to administration to the patient. In one specific example, the present invention provides a kit comprising the solid dispersion, the dispersion medium, and a syringe as described above. Alternatively, the solid dispersion and the suspension may be filled in a syringe, but may exist independently of each other in separate compartments within the syringe.

[0052] The pharmaceutical composition for parenteral administration according to the present invention can provide long-term sustained drug release of donepezil. Although not limited thereto, the pharmaceutical composition can be formulated as a drug release dosage form for 2 weeks or more, for example, 2 weeks to 2 months, 2 weeks to 5 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, or 2 months. According to the following examples, the pharmaceutical composition for parenteral administration according to the present invention can provide uniform and constant drug release over a period of 4 weeks or more. The sustained drug release period can be controlled depending on the drug loading amount (drug content ratio) during the preparation of the solid dispersion, the type of biodegradable release-controlling polymer, the blending ratio, the content of additives, etc., and related techniques are well known to those skilled in the art. Therefore, those skilled in the art can design appropriate drug release duration and release rate differently depending on the dosage of the drug to be administered to the patient, the dosage form, the severity of the disease, etc.

[0053] The parenteral pharmaceutical composition according to the present invention can be administered to patients in need of donepezil. The currently clinically approved indication for treatment with donepezil is Alzheimer's disease. The pharmaceutical composition according to the present invention may be used for the treatment of Alzheimer's disease, and more specifically, for the treatment of symptoms of Alzheimer's dementia.

[0054] The solid dispersion comprising a poorly soluble salt of donepezil and a biodegradable controlled-release polymer according to the present invention is suitable for the manufacture of a long-acting parenteral pharmaceutical composition with improved donepezil drug content. The parenteral pharmaceutical composition according to the present invention can reduce the dosage as the drug content of donepezil increases, and can significantly increase the therapeutic effect and medication compliance by maintaining the blood concentration of the drug for a long period of time. The solid dispersion comprising a poorly soluble salt of donepezil and a biodegradable controlled-release polymer according to the present invention has a relatively simple manufacturing process, does not cause the problem of initial burst drug release, and does not use an organic solvent, thereby significantly increasing safety in the body.

[0055] Figure 1 is a blood concentration-time graph showing the results of measuring blood concentration for 672 hours after administration of the compositions of Example 2, Comparative Example 1, Comparative Example 2, and Comparative Example 3.

[0056] Figure 2 shows the results of measuring blood concentration for 672 hours after administration of the compositions of Example 2, Comparative Example 1, Comparative Example 2, and Comparative Example 3 as a blood concentration-time graph (semi-log).

[0057] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited to the following examples.

[0058] Example 1. Preparation of donepezil pamoate salt microcrystals

[0059] Donepezil hydrochloride monohydrate (32.55 g, Ildong Pharmaceutical, Korea) was dissolved in 1.5 L of water (approximately 50 mM), and sodium pamoate (disodium pamoate, Sigma Aldrich, USA) was dissolved in 1.5 L of water (approximately 25 mM). The sodium pamoate solution was added dropwise to the donepezil solution while stirring at 25°C to form a precipitate. After stirring the precipitate for about 2 hours, it was centrifuged and washed three times with water to obtain solid crystals. The obtained donepezil pamoate (donepezil hemipamoate) salt crystals were stirred and suspended in 0.5 mL of water, and bead milled (MiniCer ® , Netzsch, Germany) equipment was used to micronize the drug crystals to a mean particle size of 1 to 2 μm according to the conditions in Table 1.

[0060] Bead size (mm) 0.5 Bead addition amount (g) 500 Peristaltic pump RPM 25 Milling RPM 2000 Cooling temperature (℃) 4 Milling time (h) 2

[0061] Drug crystals were obtained through centrifugation, and donepezil pamoate salt microcrystals in the form of a yellow powder were obtained through lyophilization.

[0062]

[0063] Example 2. Preparation of a solid dispersion suspension containing donepezil pamoate salt and a biodegradable release-controlled polymer

[0064] The microcrystals of donepezil pamoate salt prepared in Example 1 were mixed with different types of biodegradable release-controlling polymers and different contents of donepezil pamoate salt as shown in Table 2 below.

[0065] Types of biodegradable controlled-release polymers Content of donepezil pamoate salt (w / w%) Example 2-1 PLGA 50:50, intrinsic viscosity: 0.16 - 0.24 (Resomer ® RG 502H, Evonik, Germany)40Example 2-2PLGA 75:25, intrinsic viscosity: 0.14 - 0.22 (Resomer ® RG 752H, Evonik, Germany)40Example 2-3PLA, intrinsic viscosity: 0.16 - 0.24 (Resomer ® RG 202H, Evonik, Germany)40Example 2-4PLA, intrinsic viscosity: 0.16 - 0.24 (Resomer ® RG 202H, Evonik, Germany)50

[0066] A solid dispersion filament was manufactured using the mixture shown in Table 2 above using a high-temperature melt extruder (HAAKE MiniLab 3, Thermo Scientific, Germany) under the conditions shown in Table 3 below.

[0067] Screw type Co-rotating Nozzle type Nozzle diameter 2 mm Die heating temperature (℃) 130 Screw RPM 25

[0068] The obtained solid dispersion filament was subjected to Comil (197 Overdriven Comil) ® , Quadro, Canada) was used for dry grinding according to the conditions in Table 4 below.

[0069] Screen type 2A018R01530 (457 micron) Milling RPM 1300

[0070] 3 g of the obtained solid dispersion powder was suspended in 30 mL of 0.1% polysorbate 20 solution. The suspension was milled using a bead mill (Zentrimix ® Wet grinding was performed using equipment (380R, Netzsch, Germany) according to the conditions in Table 5 below.

[0071] Bead size (mm) 1.0 Bead addition amount (g) 20 Milling RPM 600 Cooling temperature (℃) 4 Milling time (min) 15

[0072] The undifferentiated suspension was filtered through a 200 mesh sieve (75 μm) to remove beads, centrifuged to obtain an undifferentiated composition, and lyophilized using a lyophilization device (25L Genesis SQ EL-85°, SP Scientific, USA) according to the conditions in Table 6 below.

[0073]

[0074] Freezing shelf temperature (℃) -45 Holding time (min) 180 Freezing / decompression shelf temperature (℃) -45 Holding time (min) 30 Condenser temperature (℃) -55 Initial shelf pressure (mTorr) 800 Drying stage 12345 Shelf temperature (℃) -45 -40 -100 20 Arrival time (min) 0 30 60 60 60 Holding time (min) 30 360 1440 360 360 Shelf pressure (mTorr) 200 100 100 100 100 Storage shelf temperature (℃) 20 Shelf pressure (mTorr) 200

[0075] A lyophilized solid dispersion powder containing donepezil pamoate salt in the form of a yellow powder and a biodegradable release-controlling polymer was obtained through lyophilization. The particle size of the obtained lyophilized solid dispersion powder was measured using a particle size analyzer (Mastersizer 3000, Malvern panalytical, UK) according to the conditions shown in Table 7 below.

[0076] Dispersion solvent water stirring RPM2800 shielding degree (%)20 particles refractive index1.52 measurement time (sec)10 number of measurements (times)3

[0077] The particle size analysis results of the freeze-dried solid dispersion powder are shown in Table 8.

[0078] Example 2-1 Example 2-2 Example 2-3 Example 2-4 D [4,3] 65.0 um 25.2 um 30.0 um 30.6 um Span 5.0 9 2.25 2.47 3.14 D(10) 8.38 um 6.08 um 6.07 um 5.68 um D(50) 33.0 um 19.7 um 19.4 um 18.5 um D(90) 177 um 50.3 um 53.9 um 63.7 um

[0079] The obtained freeze-dried solid dispersion powder was reconstituted into a suspension formulation according to the composition shown in Table 9 below.

[0080] IngredientsQuantity (mg / mL)Example 2-1Example 2-2Example 2-3Example 2-4Lyophilized solid dispersion powder (as donepezil)Active ingredient264.4(70)264.4(70)264.4(70)211.5(70)Carboxymethyl cellulose sodiumThickener5555Polysorbate 20Surfactant0.10.10.10.1MannitolToxicity agent50505050Water for injectionCarrierq.sq.sq.sq.s

[0081]

[0082] Comparative Example 1. Preparation of a microcrystal suspension containing donepezil freebase

[0083] A suspension was prepared from donepezil free base (Perrigo, USA) according to the composition shown in Table 10 below. Sodium carboxymethyl cellulose, polysorbate 80, mannitol, and sodium phosphate monohydrate were dissolved in water for injection, and then donepezil free base was suspended in the prepared solution.

[0084] Ingredients Quantity (mg / mL) Donepezil free base (as donepezil) Active ingredient 70 (70) Sodium carboxymethyl cellulose Thickener 10 Mannitol Tonicity agent 50 Sodium phosphate monohydrate Buffer 1 Water for injection Carrier qs

[0085] 30 mL of suspension according to the composition of Table 10 above was mixed with a bead mill (Zentrimix) ®Wet grinding was performed using equipment (380R, Netzsch, Germany) according to the conditions in Table 11 below.

[0086] Bead size (mm) 1.0 Bead addition amount (g) 20 Milling RPM 600 Cooling temperature (℃) 4 Milling time (min) 30

[0087] The undifferentiated suspension was filtered through a 200 mesh sieve (75 μm) to remove beads, and the suspension was freeze-dried using a freeze-drying facility (25L Genesis SQ EL-85°, SP Scientific, USA) according to the conditions in Table 6 of Example 2. The obtained freeze-dried powder was reconstituted into a suspension-type formulation by adding water for injection.

[0088] Comparative Example 2. Preparation of microcrystal suspension containing donepezil pamoate salt

[0089] A suspension was prepared according to the composition of Table 12 below for the microcrystals of donepezil pamoate salt prepared in Example 1. Sodium carboxymethyl cellulose, polysorbate 80, mannitol, and sodium phosphate monohydrate were dissolved in water for injection, and then the microcrystals of donepezil pamoate salt were suspended in the prepared solution.

[0090] Ingredients Quantity (mg / mL) Donepezil pamoate salt microcrystals (as donepezil) Active ingredient 105.7 (70) Sodium carboxymethyl cellulose Thickener 10 Mannitol Tonicity agent 50 Sodium phosphate monohydrate Buffer 1 Water for injection Carrier qs

[0091] The suspension according to the composition of Table 12 above was freeze-dried using a freeze-drying facility (25L Genesis SQ EL-85°, SP Scientific, USA) according to the conditions of Table 6 of Example 2. The obtained freeze-dried powder was reconstituted into a suspension-type formulation by adding water for injection.

[0092] Comparative Example 3. Preparation of a solid dispersion suspension containing donepezil free base and a biodegradable release-controlled polymer.

[0093] Biodegradable release-controlling polymers were mixed with donepezil free base (Perrigo, USA) as shown in Table 13 below.

[0094] Types of biodegradable controlled-release polymers Content of donepezil-free base (w / w%) Comparative example 3PLA, intrinsic viscosity: 0.16 - 0.24 (Resomer ® RG 202H, Evonik, Germany)40

[0095] The mixture shown in Table 13 above was lyophilized using the same method as in Example 2 to obtain a lyophilized powder containing a white powdery donepezil free base and a biodegradable release-controlling polymer. The obtained lyophilized powder was reconstituted into a suspension formulation according to the composition shown in Table 14 below.

[0096] Ingredients Quantity (mg / mL) Freeze-dried powder (as donepezil) Active ingredient 175 (70) Sodium carboxymethyl cellulose Thickener 5 Polysorbate 20 Surfactant 0.1 Mannitol Tonicity agent 50 Injection water Carrier qs

[0097]

[0098] Experimental Example 1. Pharmacokinetic (PK) test in rats

[0099] To evaluate the pharmacokinetics of the pharmaceutical compositions prepared in Example 2, Comparative Example 1, Comparative Example 2, and Comparative Example 3, a pharmacokinetics test was conducted in rats. Nine-week-old male SD rats weighing approximately 250 g were used after a 7-day acclimatization period and fasted for 12 hours prior to administration. The pharmaceutical compositions of Example 2, Comparative Example 1, Comparative Example 2, and Comparative Example 3 were administered intramuscularly to the animals, and then a pharmacokinetics analysis was performed. The composition of the test groups and administration conditions are as shown in Table 15 below.

[0100] Test group Number of animals by sex Test substance Administration route Dosage as donepezil (mg / kg) G1M4 Example 2-1 Intramuscular administration (IM) 28, Single dose G2M4 Example 2-2 Intramuscular administration (IM) 28, Single dose G3M4 Example 2-3 Intramuscular administration (IM) 28, Single dose G4M4 Example 2-4 Intramuscular administration (IM) 28, Single dose G5M4 Comparative example 1 Intramuscular administration (IM) 28, Single dose G6M4 Comparative example 2 Intramuscular administration (IM) 28, Single dose G7M4 Comparative example 3 Intramuscular administration (IM) 28, Single dose

[0101] According to the above composition, injections were performed into the left thigh, and blood samples were collected for 4 weeks as shown in Table 16 below. The collected blood was centrifuged to separate plasma and stored frozen at -70°C until analysis. The concentration of donepezil in the plasma samples was analyzed by LC-MS / MS.

[0102] Blood collection site Jugular vein Blood collection time (h) 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 24, 48, 96, 168, 240, 336, 408, 504, 576, and 672 (total 20 points) Blood collection volume (mL) 0.5 Blood collection (Blood collection) 0℃, collected in heparinized tubes Plasma separation (Plasma separation) Centrifugation at 12,000 RPM, 4℃ Storage -70℃

[0103] The results of the analysis of the concentration of donepezil in plasma samples are as shown in Figures 1, 2, and Table 17.

[0104] Test group Test substance Administration route Dose (mg / kg) C max (ng / mL)T max (h)AUC all (ng·h / mL)AUC inf(ng·h / mL)G1Example 2-1Intramuscular administration (IM) 2854.95(± 10.96) 3.50(± 3.54) 5089.1(± 808.9) 5755.8(± 267.0)G2Example 2-2Intramuscular administration (IM) 2860.70(± 14.39) 7.00(± 2.00) 6428.3(± 520.2) 7001.0(± 645.6)G3Example 2-3Intramuscular administration (IM) 2885.73(± 44.55) 2.25(± 1.55) 3949.3(± 817.2) 4650.6(± 660.1)G4Example 2-4Intramuscular administration (IM) 2846.65 (± 8.86) 5.25 (± 1.50) 3704.7 (± 288.9) 5455.9 (± 902.3) G5Comparative example 1Intramuscular administration (IM) 28247.25 (± 140.71) 3.63 (± 4.25) 8857.3 (± 2605.5) 9544.5 (± 2072.7) G6Comparative example 2Intramuscular administration (IM) 2825.81 (± 11.21) 2.31 (± 1.6) 2052.2 (± 956.9) 2410.5 (± 1172.5) G7Comparative example 3Intramuscular administration (IM) 28103.90 (± 15.90)0.88(± 0.48)6550.6(± 692.0)7006.5(± 556.1)

[0105] When the composition of Example 2 of the present invention was administered, the highest blood concentration (C) was higher than that of the composition of Comparative Example 1 and the composition of Comparative Example 3. max ) was confirmed to be lower. This indicates that donepezil pamoate salt exhibits lower solubility than donepezil free base under physiological conditions, which may result in lower initial burst drug release.

[0106] It was confirmed that when the composition of Example 2 of the present invention was administered, the blood drug concentration remained high after 168 hours compared to the compositions of Comparative Examples 1 and 2. This confirmed that when donepezil pamoate salt is encapsulated in a biodegradable release-controlled polymer, it exhibits sustained drug release under physiological conditions, and thus can exhibit an improved drug release profile for more than 4 weeks.

[0107] From these results, it was confirmed that the solid dispersion suspension containing the donepezil pamoate salt of Example 2 and the biodegradable release-controlled polymer can exhibit a low initial rapid drug release and an improved drug release profile of 4 weeks or more while containing a high drug content of 40 to 50 wt% or more.

Claims

1. A solid dispersion comprising a pharmaceutically acceptable insoluble salt of donepezil, a hydrate thereof, or a solvate thereof as an active ingredient; and a biodegradable release-controlling polymer, and having a drug content of 20 to 50 wt%.

2. In paragraph 1, A solid dispersion in which the pharmaceutically acceptable insoluble salt of the above donepezil is a pamoate, xinafoate or napadicylate salt.

3. In paragraph 1, A solid dispersion wherein the biodegradable controlled-release polymer is selected from the group consisting of polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), and mixtures thereof.

4. In paragraph 1, A solid dispersion wherein the biodegradable release-controlled polymer has a weight average molecular weight of 4,000 to 50,000.

5. In paragraph 1, A solid dispersion wherein the biodegradable release-controlled polymer has an inherent viscosity of 0.1 to 1 dl / g.

6. In paragraph 1, The above solid dispersion is a solid dispersion manufactured by high temperature melt extrusion.

7. In paragraph 1, The above solid dispersion has an average particle size of 1 to 100 um.

8. A step of forming a solid dispersion filament by high-temperature melt extrusion of a mixture of a pharmaceutically acceptable insoluble salt of donepezil, a hydrate thereof, or a solvate thereof as an active ingredient; and a biodegradable release-controlled polymer. Comprising a step of crushing and finely dividing the above solid dispersion filaments, A method for producing a solid dispersion according to any one of claims 1 to 7.

9. In paragraph 8, A method for producing a solid dispersion, further comprising the step of freeze-drying the above-mentioned undifferentiated solid dispersion.

10. A pharmaceutical composition for parenteral administration comprising a solid dispersion according to any one of claims 1 to 7.

11. In paragraph 10, The above pharmaceutical composition is a pharmaceutical composition for parenteral administration that is a suspension.

12. In paragraph 10, The above pharmaceutical composition is a pharmaceutical composition for parenteral administration in the form of an injection.

13. In paragraph 12, The above-mentioned injection is a pharmaceutical composition for parenteral administration suitable for subcutaneous or intramuscular administration.

14. In paragraph 10, The above pharmaceutical composition is a pharmaceutical composition for parenteral administration that is a drug release formulation for 2 to 5 weeks.

15. In paragraph 10, The above pharmaceutical composition is a pharmaceutical composition for the treatment of Alzheimer's disease.

16. A kit comprising a solid dispersion, a dispersion medium, and a syringe according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Preparation method of slow-release medicinal donepezil hydrochloride composition

    CN107252421A

  • Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same

    KR101659983B1

  • Method of preparing pharmaceutical composition formed double-melt exterusion and the pharmaceutical composition using the same

    KR101801476B1

  • Pharmaceutical composition comprising donepezil for parenteral administration

    KR101811797B1